Deans' stroke musings: Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark, 1996

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, August 17, 2020

Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark, 1996–2016

SO FUCKING WHAT? YOU'RE NOT EVEN MEASURING THE ONLY GOAL IN STROKE, 100% RECOVERY.

Do you never talk to survivors?

Time trends in incidence, comorbidity, and mortality of ischemic stroke in Denmark, 1996–2016E

Adelina Yafasova, Emil Loldrup Fosbøl, , Naja Emborg Vinding, Charlotte Andersson, Christina Kruuse, Søren Paaske Johnsen, Gunnar Hilmar Gislason, Christian Torp-Pedersen, Lars Køber,

First published August 14, 2020, DOI: https://doi.org/10.1212/WNL.0000000000010647

Full PDF

Citation

Permissions

Make Comment

See Comments

Downloads

Add to Cart ($39)

Abstract

Objective To examine whether the incidence, comorbidity, and mortality of first-time ischemic stroke changed in Denmark between 1996 and 2016 overall and according to age and sex using a nationwide cohort design.

Methods In this cohort study, 224,617 individuals ≥18 years admitted with first-time ischemic stroke between 1996 and 2016 were identified using Danish nationwide registries. We calculated annual age-standardized incidence rates and absolute 30-day and 1-year mortality risks. Further, we calculated annual incidence rate ratios using Poisson regression, odds ratios for 30-day mortality using logistic regression, and hazard ratios for 1-year mortality using Cox regression.

Results The overall age-standardized incidence rates of ischemic stroke per 1,000 person-years increased from 1996 (2.70 [95% CI, 2.65–2.76]) to 2002 (3.25 [95% CI, 3.20–3.31]) and then gradually decreased to below the initial level until 2016 (1.99 [95% CI, 1.95–2.02]). Men had higher incidence rates than women in all age groups except 18–34 and ≥85 years. Absolute mortality risk decreased between 1996 and 2016 (30-day mortality from 17.1% to 7.6% and 1-year mortality from 30.9% to 17.3%). Women between 55 and 64 and ≥85 years had higher mortality than men. Similar trends were observed for all analyses after multivariable adjustment. The prevalence of atrial fibrillation, hypertension, diabetes mellitus, and use of lipid-lowering medication increased during the study period.

Conclusions The age-standardized incidence of first-time hospitalization for ischemic stroke increased from 1996 to 2002 and then gradually decreased to below the initial level until 2016. Absolute 30-day and 1-year mortality risks decreased between 1996 and 2016. These findings correspond to increased stroke prevention awareness and introduction of new treatments during the study period.